TransMedics Group, Inc. (TMDX) Stock Forecast
TMDX analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.15 / 5 from 13 analysts
- Price target
- $98.73 average of analyst targets
- Upside to target
- +39.5% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $0.27
- 52-week range
- $62.04 – $150.42
TMDX analyst ratings
13 analystsNumber of analysts at each rating.
TMDX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TMDX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.29 | $0.15 | $0.40 | $0.66 | −55.5% | 10 |
| Current fiscal year (2026) | $1.51 | $1.17 | $1.63 | $2.63 | −42.4% | 10 |
| Next fiscal year (2027) | $2.25 | $1.61 | $3.04 | $1.51 | +49.0% | 10 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TMDX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $178.1M | $169.9M | $188.4M | +23.8% | 12 |
| Current fiscal year (2026) | $742.2M | $727.5M | $753.0M | +22.6% | 13 |
| Next fiscal year (2027) | $874.7M | $859.4M | $915.0M | +17.8% | 12 |
TMDX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TMDX revenue: reported and forecast
TMDX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.39 | $0.30 | $0.29 | $0.29 | $0.29 | −24.8% | 0 up · 2 down |
| Current fiscal year (2026) | $1.77 | $1.56 | $1.54 | $1.51 | $1.51 | −14.6% | 0 up · 3 down |
| Next fiscal year (2027) | $2.77 | $2.31 | $2.31 | $2.25 | $2.25 | −18.5% | 0 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TMDX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TMDX beat in 7 of 12.
What analysts expect from TMDX
13 analysts cover TransMedics; their consensus rating is buy (4.15 on a 1–5 scale, where 5 is a strong buy). The average price target is $98.73, 39.5% above the latest close of $70.78. Analysts expect earnings of $1.51 per share for 2026, −42.4% from a year earlier. For 2027 the average estimate is $2.25 per share on revenue of $874.7 million. TransMedics beat the EPS estimate in 7 of the last 12 quarters.
Related: TMDX income statement, TMDX key metrics, TMDX chart. See the TMDX stock overview for the latest quote and news.
TMDX forecast FAQ
What is TransMedics's price target?
The average analyst price target for TransMedics is $98.73, 39.5% above the latest close of $70.78.
Is TransMedics a buy, hold or sell?
Of 13 analysts covering TransMedics, 6 rate it a strong buy, 3 a buy, 4 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is TransMedics's EPS forecast?
Analysts forecast $1.51 per share for 2026 (range $1.17 to $1.63); for 2027 the estimate is $2.25.
What is TransMedics's revenue forecast?
The average revenue estimate for 2026 is $742.2 million, growth of 22.6%; for 2027 it is $874.7 million.
When does TransMedics report earnings?
TransMedics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026; the EPS estimate is $0.27.
Does TransMedics usually beat earnings estimates?
TransMedics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.